# A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer

> **NCT02066961** · — · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 1533 (actual)

## Conditions studied

- Prostate Cancer
- Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02066961
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-31
- **Primary completion:** 2019-11-14
- **Final completion:** 2019-11-14
- **Target enrollment:** 1533 (ACTUAL)
- **Last updated:** 2019-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02066961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02066961, "A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02066961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*